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Introduction: In recent years, a new concept of an anticancer vaccine has been proposed to 
prevent and control the proliferation and expansion of cancer cells by eliciting an immune boost 
in biological systems. The recent literature supports the role of embryonic stem cells (ESC) as 
cellular agents that stimulate the biological systems to destroy cancer cells. However, at present, 
a true anticancer vaccine remains elusive. There are several lines of evidence showing that carbon 
nanotubes may be used to initiate and maintain immune responses. 
Objective: The authors proposed to test the therapeutic potential of multiwalled carbon 
nanotubes (MWCNTs) combined with ESC as agents to induce an immune boost and provide 
subsequent anticancer protection in mice. 
Methods: C57 BL/6 mice were immunized with ESC and MWCNTs. 
Results: The proposed vaccine led to significant antitumor responses and enhanced tumor 
rejection in mice with subcutaneous inoculation of MC38 colon malign cells compared with 
groups only administered ESC, only MWCNTs, and controls. 
Conclusion: The application and potential of ESC combined with MWCNTs as anticancer 
immunization agents may represent the beginning of a new chapter in the treatment of colon cancer.
Keywords: carbon nanotubes, embryonic stem cells, synergistic enhancement, immunization, 
colon cancer, vaccine
Introduction
Colon cancer is a major cause of mortality worldwide, and this is expected to rise in the 
coming years.1 Current therapeutic strategies in colon cancer include surgical resection 
of the primary tumor, chemotherapeutic drugs, and radiotherapy.2 The development of 
nanoscale drug delivery systems represents an exciting and new approach to cancer 
treatment.3 The ultimate aim when using nanoscale drug systems is delivery of high doses 
of active bionanomolecules at specific sites while simultaneously reducing systemic 
toxicity.4 Very recent clinical trials suggest that nanoscale drug delivery systems, such as 
doxorubicin encapsulated in liposomes (Doxil®)5 and paclitaxel attached to nanoparticles 
(Abraxane®),6 could prolong survival in advanced cancer. One remarkable property of 
these nanosystems is their ability to activate the immune system, which could form 
an attractive basis for development of a cancer vaccine.7 Although such drug delivery 
systems hold tremendous potential for the future prevention of cancer, a true anticancer 
vaccine remains elusive.8 Nanotechnology has already shown promising results in the 
field of anticancer vaccines. For instance, inert nanobeads, recombinant virus-like 
particles, and immunostimulating complexes, are being used in cancer vaccine research 
due to their efficacy at eliciting both cellular and humoral immune responses.9International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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During the last decade, advances in functionalization 
chemistry have been one of the driving forces in the develop-
ment of new classes of allotropes of carbon for applications 
in biology and medicine.10–14 Due to their unique physical and 
chemical properties, carbon nanotubes hold great promise for 
drug delivery and cancer therapy.15 There are encouraging data 
suggesting that carbon nanotubes may be used to initiate and 
maintain immune responses.16 When bound to tumor antigens, 
carbon nanotubes elicit a specific antitumor response in animal 
models.17 Furthermore, it has been shown that peptide-function-
alized carbon nanotubes can act as proficient immunomodula-
tors and consequently generate specific antibody responses.18 
Moreover, ex vivo clonal expansion of T cells with antibody-
linked carbon nanotubes results in T cell activation and might 
lead to the development of novel immunotherapies.19
It has been shown in animal models that significant 
lymphocyte proliferation and secretion of cytokines may help 
to rebuild host immunity against cancer and consequently 
generate obvious antitumor immunity. Despite their proven 
role in proliferation of T lymphocytes, especially the 
proliferation of CD8+ (cytotoxic T) lymphocytes,19 which 
are the main antitumor effector cells,20,21 there are currently 
no studies that explore the concept of cancer prophylaxis 
mediated by carbon nanotubes.
Recently published data support the role of embryonic 
stem cells (ESC) as a cellular cancer vaccine that stimulates 
biological systems to destroy colon cancer cells by eliciting 
an immune boost.22 This implication is supported by the fact 
that ESC prevent and control proliferation and expansion of 
malignant tumors in vivo by formation and development of 
CD4+ and CD8+ T lymphocytes.23
Considering all these data together, we hypothesized that 
combined administration of both ESC and carbon nanotubes 
would function as a powerful nanobiosystem to induce and 
rebuild antitumor immunity in colon tumor animal models. 
Here we demonstrate that simultaneous immunization with 
ESC and MWCNT leads to significant antitumor responses and 
enhanced tumor rejection in mice with subcutaneous inocula-
tion of malignant colon cells. The application and potential of 
ESC and MWCNT as anticancer vaccines may represent the 
beginning of a new chapter in the treatment of colon cancer.
Materials and methods
carbon nanotubes
MWCNT self-assembled into bundles (.99% carbon 
basis, 8–15 nm [outside diameter] × 3–5 nm [inside 
diameter] × 10–50 µm [length]) were purchased from Sigma 
Chemical Company, Deisenhofen, Germany (Figure 1A). 
The nonconjugated highly purified MWCNT control solution 
was prepared as previously described.24 The product obtained 
was diluted in physiological saline solution (NaCl 0.9%) at 
a 1:10 (v/v) ratio.
cell lines
C57 BL/6 mouse ESC were purchased from the American 
Tissue Culture Collection (ATCC), and cultured in mouse 
ESC growth medium on plates precoated with gelatin 
  solution and C57 BL/6 mouse embryonic fibroblasts (ATCC) 
as feeder cells (Figure 1B). For use as cellular therapy, ESC 
were centrifuged (1000 rpm/10 minutes) and the supernatant 
discarded. The viability of ESC cells was assessed using the 
0.4% Trypan blue dye method prior to administration. Cell 
concentrations were adjusted to 1 × 105 cells/µL.
Mice
Six-week-old C57 BL/6 female mice weighing 20–25 g were 
purchased from Jackson Laboratory (Bar Harbor, ME) and 
housed under sterile conditions in laminar air flow cabinets in 
accordance with standard guidelines. All animal experiments 
were approved by the Institutional Ethics Committee.
Vaccine administration
Forty C57 BL/6 mice were randomly divided into four 
groups. The first group received 1 × 106 C57 BL/6 ESC 
(inoculated subcutaneously) weekly for 6 weeks; the   second 
group received 300 µL of about 0.1 mg/mL MWCNT 
intravenously administered into the tail vein for 6 weeks   
(at 1-week intervals); the third group received both C57 BL/6 
B
C A
Figure  1  (A) Transmission  electron  micrographs  of  MWcNTs  used  for  the 
immunization. The  scale  bar  represents  100  nm.  (B)  In  vitro  c57  BL/6  mouse 
embryonic  stem  cells  used  for  immunization  (scale  bar:  50  µm).  (C)  schematic 
illustration of the proposed vaccine.
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ESC and MWCNT at the same concentrations (1 × 106 C57 
BL/6 ESC + 300 µL of approximately 0.1 mg/mL MWCNT, 
injected separately, at the same administration intervals, ie, 
weekly for 6 weeks); and the control group received 1 mL 
of physiological saline solution in the tail vein in accordance 
with the above administration schedule.
Mc38 murine colon cancer xenografts
After 6 weeks of administration (physiological saline 
solution, ESC, MWCNT, or ESC + MWCNT), MC38 
(ATCC) colon cancer cells were injected subcutaneously into 
the mice, according to a previously described method.22,23,25 
Subcutaneous tumor size was measured every 3 days using 
digital vernier calipers. Tumor volume was calculated based 
on three axis measurements.22
Lymphocyte counts
At the end of immunization (physiological saline solution, 
ESC, MWCNT, or ESC + MWCNT), citrate-anticoagulated 
blood was acquired from the venous sinus of the eye orbit26 
in mice from all groups. Sampled blood was stained with 
antibodies for CD4+ and CD8+ (BD Bioscience Pharmingen, 
San Diego, CA) for sorting T lymphocytes by a Beckman 
CellLAb Quanta flow cytometer (Beckman Coulter, 
Indianapolis, IN).23
Antigen-specific T cell response
Spleens were aseptically removed from selected sacrificed 
animals in the treatment and control groups at the end of 
the study. Each spleen was cut into small pieces in RPMI-
1640 medium (Sigma, St Louis, MO) and rinsed through 
40 mesh stainless steel screens. Cell suspensions were further 
purified by Ficoll-Hypaque gradient centrifugation.
The frequencies of interferon-gamma (IFN-γ) and tumor 
necrosis factor (TNF)-secreting CD8 T lymphocytes in a 
splenocyte population were determined by intracellular 
cytokine staining. Cells were fixed in 2% paraformaldehyde, 
permeabilized with PermWash buffer (Pharmingen), 
and incubated with anti-IFN-γ allophycocyanin antibody 
(BD Biosciences) and anti-TNF-phycoerythrin antibody 
(Abcam, Cambridge, UK). Samples were acquired on a 
Beckman CellLAb Quanta flow cytometer, and the data 
were analyzed using CellQuest software (Becton Dickinson 
Immunocytometry Systems, San Jose, CA).
Immunohistochemistry analysis
On day 21 following subcutaneous inoculation of MC38 
colon cancer cells (this was considered the endpoint of 
the study) the mice were sacrificed. Tumors and spleens 
were excised and immersed in 4% formaldehyde solution. 
The tissues were embedded in paraffin wax and serially 
  sectioned. Tissue sections were deparaffinized and rehydrated 
in a graded ethanol series followed by incubation with 3% 
hydrogen peroxide for 15 minutes, and 15-minute rinses in 
three changes of phosphate-buffered saline. Next, in order to 
suppress nonspecific background staining, the sections were 
blocked with normal goat serum. The diluted (1:100) rabbit 
antimouse CD4 and CD8 antibodies (Sigma) were applied 
to the sections at 4°C for 12 hours. Quantification of CD4+ 
or CD8+ lymphocytes was performed using the mean optical 
density method as described elsewhere.27 The sections were 
then incubated with biotinylated goat antirabbit IgG for 
30 minutes at room temperature and processed according to 
the manufacturer’s protocol. Specific visualization of tissues 
was performed using an Olympus BX60 light microscope 
equipped with a camera system (Hamburg, Germany).
TUNeL assay
The sections harvested from tumors at the endpoint (on day 21 
following subcutaneous inoculation of colon cancer cells) were 
incubated with protease K for 30 minutes at room temperature 
for antigen retrieval and further prepared according to the 
TUNEL TMR red apoptosis detection kit (Roche Applied 
Science, Branford, CT). The red-labeled TUNEL-positive 
cells were visualized under a fluorescent microscope (LP585 
emission). Quantification of positively stained nuclei was 
performed using the mean optical density method.
cytokine expression
Fresh blood from all mice was obtained at the same time and 
in the same way as previously described, and serum was col-
lected. Quantification of interleukin (IL)-10 IL-2, and IFN-γ 
was performed using commercially available enzyme-linked 
immunosorbent assay kits (Sigma) in accordance with the 
manufacturer’s instructions and analyzed on an enzyme-linked 
immunosorbent assay reader (Labsystem Multiskan Plus, Hel-
sinki, Finland). Minimum detectable cytokine concentrations 
for these assays as provided by the manufacturer were IL-2 
(4 pg/mL), IL-10 (2 pg/mL), and IFN-γ (4 pg/mL).
electron microscopy imaging
The ultrastructural morphology of MWCNT was evaluated 
using a Jeol JEM 1010 transmission electron microscope 
(Jeol, Tokyo, Japan) as previously described.28 The images 
were captured using a Mega VIEW III camera (Olympus, 
Soft Imaging System, Münster, Germany).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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statistical analysis
All data were expressed as means ± standard error of the mean. 
Continuous data were tested for normality (Kolmogorov-
Smirnov test) before hypothesis testing. Longitudinal data, 
representing repetitive measurements of the same parameter 
during the follow-up interval, were analyzed by construction 
of a kinetic curve along with area under the curve calculus. 
Consecutively, kinetic curves of two different groups were 
compared using the Mann-Whitney U test. Fisher’s Exact test 
was used for qualitative data correlations. For all tests, a 0.05 
threshold was selected for statistical significance. Statistical 
data analysis was performed using SPSS 17.0 software (SPSS 
Inc, Chicago, IL).
Results and discussion
The first in vitro published observation of the potential of 
embryonic materials as a vaccine to prevent the development 
of tumor xenografts in animal models29 stimulated significant 
interest and research, leading to rapid development in this 
field. Preliminary data support the role of ESC as effective 
cellular agents that reverse the immune dysfunction that 
causes cancer and induces antitumor immunity in tumor-
loading mice of different stages.23 On the other hand, several 
authors have suggested that carbon nanotubes have impressive 
immunomodulatory properties and are shown to enhance 
both the kinetics and magnitude of T cell and macrophage 
activation.19 It is well known that one of the reasons for 
failure of the immune system to eliminate a tumor mass is 
lack of appropriate activation of the lymphocyte population 
to a threshold required for tumor rejection.30 Given these 
data and the described role of MWCNT in proliferation of 
lymphocytes, we reasoned that administration of both carbon 
nanotubes and ESC would provide a better immune response 
and stronger antitumor immunity (Figure 1C).
Outcome and biodistribution after 
administration of MWcNT
Neither mortality nor significant loss of body weight was 
observed in any of the mice among the four study groups 
during the 9-week period of the study. These findings are 
similar to other reports showing 100% long-term survival in 
mice following MWCNT administration at similar doses.31 
Following administration, MWCNT deposits were found in 
the liver, spleen, kidney, and lungs, but not in tumor tissue.
Despite their unique features, the toxicity and biological 
interactions of carbon nanotubes represent a major concern, 
with several authors pointing to their similarity to asbestos 
fibers.32 Many factors attributed to carbon nanotubes, such 
as biofunctionalization, length, concentration, duration of 
exposure, and methods of dispersion, have been associated 
with carbon nanotube toxicity in both in vitro and in vivo 
studies.33
To date, few in vitro experiments assert that oxidative 
stress from carbon nanotubes is a major result of toxicity. 
However, most of the studies suggesting that carbon 
nanotubes are nontoxic in vivo outnumber those proposing 
otherwise. It has been stated that the toxicity of carbon 
nanotubes is negligible in mice with chronic exposure to 
carbon nanotubes.16
Tumor development
Following administration of the proposed vaccines, the 
kinetics of tumor growth in the MC38 colon cancer model 
were closely monitored (Figure 2A and C). Importantly, 
following treatment, volumetric evolution of the tumors 
(Figure 2A) revealed that, as compared with ESC, MWCNT, 
and the control group, the area under the curve corresponding 
to the ESC + MWCNT group was significantly lower 
(ESC + MWCNT versus ESC, P = 0.021; ESC + MWCNT 
versus MWCNT, P = 0.014). Moreover, in the ESC and 
MWCNT groups, the tumor growth rate was also significantly 
slower compared with the control group (ESC versus 
physiological saline solution, P = 0.042; MWCNT versus 
physiological saline solution, P = 0.048). This finding 
suggests a strong and stable antitumor response in mice 
using ESC, MWCNT, or ESC + MWCNT. However, the most 
significant tumor rejection was found in the ESC + MWCNT 
group, and was significantly higher than that in the other 
groups. We further compared the weights of tumors harvested 
on day 21 following administration of therapy and induction 
of carcinogenesis. Similarly, we observed that tumor 
weights were significantly lower for the ESC + MWCNT 
group compared with the control, ESC, and MWCNT 
groups (Figure 2B). Moreover, clinical expression (when 
subcutaneous tumors became palpable and measurable) of 
the colon cancer xenografts was also significantly delayed 
in the ESC + MWCNT group (Figure 2C). These results 
show that mice treated with ESC + MWCNT acquired 
significant antitumor immunity and prevented tumor masses 
from propagating and developing compared with the other 
groups.
Proliferation of lymphocytes in peripheral 
blood of mice
We next investigated the proliferation of both T and B 
lymphocytes in the peripheral circulation of all groups International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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of mice (Figure 3A). Notably, the absolute numbers and 
percentages of CD4+ and CD8+ cells in the ESC, MWCNT, 
and ESC + MWCNT groups were significantly higher 
compared with the control group (P , 0.05 in all cases). We 
observed almost similar levels of CD4+ and CD8+ T cells in 
the ESC and MWCNT groups (Figure 3A). Importantly, the 
proliferation of both CD4+ and CD8+ in the ESC + MWCNT 
group was significantly higher than in the ESC and MWCNT 
groups (P , 0.05). Therefore, both CD4+ and CD8+ T cells 
were induced in response to ESC + MWCNT vaccination. 
Consequently, antitumor immunity was generated.34 We also 
examined the ratio of CD4+/CD8+ lymphocytes. As shown in 
Figure 3B, there were more cytotoxic lymphocytes (CD8+) 
generated in the MWCNT + ESC group, suggested by a lower 
ratio of CD4+/CD8+ (P , 0.05) compared with the other 
groups. This finding is of importance because CD8+ T cells 
are potent mediators of antitumor immunity.35,36 Moreover 
CD4+ T cells are also important in antitumoral immunity 
because, in their absence, CD8+ T cells can be depleted or 
lose their immunogenic capacity.36,37 Therefore, cell therapies 
that rely on CD4+ T cells are far superior to therapies that 
only use CD8+ T cells.38 In the present study, following 
combined administration of MWCNT and ESC, we have 
obtained increased proliferation of both CD4+ and CD8+ 
lymphocytes, which constitutes the main part of antitumor 
effector cells.23,39–41
Proliferation of lymphocytes in spleen  
of mice
Figure 4 shows the proliferation of CD4+ and CD8+ 
immunostained lymphocytes in splenic tissue harvested 
at the endpoint. It is evident that larger numbers of CD4+ 
and CD8+ cells were found in the ESC + MWCNT 
vaccine groups compared with the ESC, MWCNT, and 
control group, and this finding was statistically significant 
(P , 0.05). This increased proliferation of lymphocytes was 
responsible for protection of ESC + MWCNT-vaccinated 
animals from tumor development. The mean optical 
density for CD4+ T lymphocytes was 0.09 ± 0.018 for 
the physiological saline solution group, 0.21 ± 0.036 for 
the ESC group, 0.24 ± 0.023 for the MWCNT group, and 
0.31 ± 0.054 for the ESC + MWCNT group. For CD8+ 
T lymphocytes, the mean optical density was 0.12 ± 0.028 
for the physiological saline solution group, 0.24 ± 0.043 for 
the ESC group, 0.22 ± 0.037 for the MWCNT group, and 
0.34 ± 0.064 for the ESC + MWCNT group. For both CD4+ 
and CD8+, there was a statistically significant (P , 0.01) 
increase in proliferation of lymphocytes in the spleens of 
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mice treated with ESC + MWCNT as compared with the 
controls (Figure 4).
cytokine expression
In order to shed light on the molecular mechanism 
involved in antitumor immunity, we next examined whether 
ESC + MWCNT immunization resulted in production of 
antitumor-specific cytokines by lymphocytes in serum. 
The process of rejection of cancer cells requires T cell 
immunity. Two types of T helper cells, categorized as Th1 
and Th2 on the basis of cytokine production, have been 
reported to play a crucial role in regulating anticancer 
immune responses.42 Th1 cells produce IL-2 and IFN-γ, 
while Th2 cells secrete IL-4, IL-6, and IL-10. Th1 cells 
mediate cellular immunity, and Th2 cells support tumoral 
immune responses. The cytokines produced by Th1 and 
Th2 cell subsets are important for the function and immune 
response of cytotoxic T lymphocytes because they can 
regulate the differentiation of these cells.43–45 Besides 
the decrease in quantities of lymphocytes, the cytokines 
secreted by CD4+ lymphocytes in a Th1/Th2 shift state is 
another abnormality of lymphocyte homeostasis induced 
by carcinogenesis.46,47 As a result, this state is expressed by 
an increase in Th2 cytokines (IL-4, IL-6, IL-10) combined 
with a decrease in Th1 cytokines (IL-2, 3, IFN-γ). We 
analyzed the concentration of IL-10, IL-2, and IFN-γ by 
enzyme-linked immunosorbent assay (Figure 3C). The 
results suggested that mice in the ESC + MWCNT vaccine 
group had significantly increased expression of IL-2 
and IFN-γ (P , 0.05). However, there was no difference 
in IL-10 levels between the groups. This suggests that 
administration of ESC + MWCNT activated secretion 
of Th1 cytokines, which comprises an important part of 
antitumor immunity. Furthermore, the statistical difference 
between the treatment groups ESC + MWCNT and ESC or 
MWCNT suggested that administration of ESC + MWCNT 
could stimulate the immune system more effectively to 
generate lymphocytes and cytokines. Due to the altered 
expression of proteins involved in antigen processing and 
presentation, tumor cells are able to avoid recognition 
by the immune system, and insufficient activation of 
antitumor immunity led to poor protective responses.23,48,49 
Both an increase in lymphocytes and cytokine secretion 
following ESC + MWCNT were observed in our study. 
Thus, the proposed vaccine accomplished the reversal of 
the existing immune dysfunction, further stimulating the 
host immune protective responses. Altogether, these data 
indicate that tumor-specific T cell immunity is enhanced 
after ESC + MWCNT administration in C57 BL/6 mice.
Molecular mechanisms of immune boost 
induced by MWcNT administration
Several reports show a significant antitumor response when 
TNF-immunodeficient mice are treated with TNF, suggesting 
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that TNF plays an important role in antitumor immunity.50 
Most data indicate that TNF stimulates innate immunity both 
in vitro and in animal models and stimulates the production 
of other cytokines (eg, IL-1, IL-6, and IL-8) and cytotoxic 
agents (eg, nitric oxide and reactive oxygen species) by 
macrophages, which can further mediate tumor suppression.51 
Alternatively, IFN-γ enhances antitumor responses by 
optimizing access of antigens to HLA class I52 or by signaling 
through the IFN-γ receptor on CD8+ T lymphocytes.53 
In order to clarify the mechanism of the synergistic antitumor 
effect induced by the administration of MWCNT, we next 
examined IFN-γ and TNF production in CD8+ T lymphocytes 
harvested from splenic tissue in mice. For this purpose, 
IFN-γ and TNF-secreting CD8+ T lymphocyte populations 
were examined in splenocytes harvested from mice at the 
endpoint.
As shown in Figure 5, we found that MWCNT administra-
tion in mice strongly enhanced production of IFN-γ-secreting 
and TNF-secreting CD8+ T cells (P , 0.001). In contrast, no 
significant difference in IFN-γ-secreting and TNF-secreting 
CD 8+ production in mice vaccinated with physiological 
saline solution or ESC was observed. These results strongly 
suggest that MWCNT synergistically enhance the antitumor 
effect by generating IFN-γ and TNF CD8+ cells.
TUNeL assay
When the mice were sacrificed, we detected cell apoptosis in 
tumor tissues using the TUNEL TMR kit (Figure 6). DNA 
disintegration as a result of cellular apoptosis may yield 
double-stranded and single-stranded DNA breaks (nicks). 
These nicks can be discovered by labeling free 3′-OH termini 
with modified nucleotides, such as fluorescein-dUTP, in an 
enzymatic reaction. This method is recognized for its high 
sensitivity and specificity for apoptotic cell detection in tissue 
sections.54 The mean optical density of red labeled apoptotic 
nuclei was 0.043 ± 0.038 for the physiological saline solu-
tion group, 0.07 ± 0.046 for the ESC group, 0.058 ± 0.063 
for the MWCNT group, 0.12 ± 0.14 for the ESC + MWCNT 
group. Thus, we found that apoptosis of tumor cells in the 
ESC + MWCNT vaccine group was higher from that of the 
control group (P , 0.05) and the increase was marginally 
significant compared with the ESC or MWCNT groups 
(P = 0.067 for ESC; P = 0.072 for MWCNT). However, 
no significant difference was found between the ESC and 
MWCNT groups. These results suggest that immunization 
with MWCNT and ESC could lead to significant protection 
against development of colon cancer. It has been shown that 
ESC suppress colon cancer growth by CD8+ T and CD4+ T 
Figure 6 cellular apoptosis in tumoral tissue harvested at the endpoint (A) control, 
(B) esc, (C) MWcNTs, (D) esc+MWcNTs.
Abbreviations: esc, embryonic stem cells; MWcNT, multiwalled carbon nanotube.
cell activation.22 Furthermore, it has also been reported that 
CNTs are involved in activation of the immune response.19,55,56 
In our study, we discovered a novel application of carbon 
nanotubes, ie, anticancer immunization. This prophylactic 
anticancer effect was even more pronounced when MWCNT 
were combined with ESC, and we showed here that systemic 
administration of MWCNT synergistically enhances the 
antitumor effect of ESC in mice.
Conclusion
The application of carbon nanotube immunotherapy 
represents a new paradigm in cancer treatment development. 
Our research could open new avenues for how cancer 
vaccines could be successfully developed in the future. 
These results are very encouraging because, for the first 
time, a combination of carbon nanotubes and embryonic 
stem cells has successfully provided activation of antitumor 
immunity, leading to impressive suppression of proliferation 
and development of malignant colon tumors. Although 
our approach has shown very promising results in murine 
models, in vivo toxicity studies of MWCNT are now 
required.
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